3.3. Danazol

Publisher： Nova Science Publishers, Inc.

ISSN： 1554-1134

Source： International Journal of Cancer Research and Prevention, Vol., Iss., 2017-01, pp. : 84-83

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study

By Covens A.   Brunetto V.L.   Markman M.   Orr J.W.   Lentz S.S.   Benda J.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 470-474

Elsevier

Access to resources Recommend Favorite

IL33 and kidney disease (Review)

By          

Molecular Medicine Reports, Vol. 13, Iss. 1, 2016-01 ,pp. : 3-8

Spandidos Publications

Access to resources Recommend Favorite

A33 antigen displays persistent surface expression

By Ackerman Margaret   Chalouni Cecile   Schmidt Michael   Raman Vivek   Ritter Gerd   Old Lloyd   Mellman Ira   Wittrup K.  

Cancer Immunology, Immunotherapy, Vol. 57, Iss. 7, 2008-07 ,pp. : 1017-1027

Springer Publishing Company

Access to resources Recommend Favorite

ADAM33 polymorphisms are associated with asthma and a distinctive palm dermatoglyphic pattern

By      

Molecular Medicine Reports, Vol. 8, Iss. 6, 2013-01 ,pp. : 1795-1800

Spandidos Publications

Access to resources Recommend Favorite

IL33 levels differentiate tuberculous pleurisy from malignant pleural effusions

By          

Oncology Letters, Vol. 8, Iss. 1, 2014-01 ,pp. : 449-453

Spandidos Publications

Access to resources Recommend Favorite